Mglur3 (Grm3) Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Neurons expressing metabotropic glutamate receptor 3 (mGluR3/GRM3), a group II metabotropic glutamate receptor with both neuronal and glial expression patterns. GRM3 is a G protein-coupled receptor that primarily signals through Gi/o proteins, inhibiting adenylate cyclase and reducing cAMP production. This receptor plays crucial roles in regulating glutamatergic neurotransmission, synaptic plasticity, and neuroprotection throughout the central nervous system. [1]
GRM3 is widely expressed across multiple brain regions: [2]
mGluR3 is found on both presynaptic and postsynaptic elements: [3]
GRM3 encodes a 879-amino acid protein belonging to class C metabotropic glutamate receptors: [4]
mGluR3 activates multiple intracellular signaling cascades: [5]
Gi/o Protein Signaling
ERK/MAPK Pathway
PI3K/Akt Pathway
PLC-independent signaling
Neurons expressing mGluR3 exhibit distinct electrophysiological characteristics: [6]
mGluR3 plays a complex role in synaptic plasticity: [7]
GRM3-expressing neurons receive inputs from:
These neurons project to:
GRM3 has emerging relevance in Alzheimer's disease pathogenesis:
In Parkinson's disease, GRM3-expressing neurons are affected through:
While not primarily a neurodegenerative condition, GRM3 genetic variants are associated with:
GRM3 represents a promising therapeutic target:
Several compounds targeting group II mGluRs have been investigated:
GRM3 knockout mice exhibit:
Mouse models with neuronal GRM3 overexpression show:
The study of Mglur3 (Grm3) Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Niswender CM, Conn PJ. (2010). Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annual Review of Pharmacology and Toxicology. 2010. ↩︎
Marek GJ, et al. (2010). Metabotropic glutamate mGlu3 as a target for novel antidepressant drugs. Neuropharmacology. 2010. ↩︎
Benneyworth MA, et al. (2011). A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a late-phase LTP in hippocampal area CA1. Neuropharmacology. 2011. ↩︎
Joffe ME, et al. (2019). mGlu3 and mGlu5 metabotropic glutamate receptors co-localize and interact in corticostriatal astrocytes. Glia. 2019. ↩︎
Lyon L, et al. (2021). Group II metabotropic glutamate receptors in neurodegeneration: new targets for neuroprotection. Neurobiology of Disease. 2021. ↩︎
Takao K, et al. (2022). GRM3 deficiency leads to enhanced amyloid-beta pathology in mouse models. Journal of Alzheimer's Disease. 2022. ↩︎
Zhang Y, et al. (2023). Astrocytic mGluR3 regulates synaptic transmission and cognitive function in Alzheimer's disease. Cell Reports. 2023. ↩︎